A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19

NCT ID: NCT04834128

Last Updated: 2023-04-21

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-13
• Study Completion Date: 2022-04-13

Brief Summary

A Phase II safety and tolerability study of expanded gamma delta T cell lymphocytes (TCB008) in patients diagnosed with COVID-19.

Detailed Description

The aim of this Phase II study is to evaluate the safety and tolerability of ex-vivo expanded gamma delta T-cells (TCB008) manufactured from a single allogeneic unmatched or partially, randomly matched, unrelated donor, in patients with COVID-19.

The trial is designed to identify an optimal, safe dose of allogeneic γδ T cells in a population of patients with COVID-19. There will be 4 patient Cohorts. Cohorts 1 - 3 will receive a pre-defined dosing schedule, with Cohort 4 being treated with a dose selected upon completion of the first 3 Cohorts. In order to investigate immunogenicity assessment/sensitisation effects, patients in the expansion cohort who do not experience adverse reactions meeting dose limiting toxicity (DLT) criteria after the first administration will receive re-infusion with the same dose on Day 10 after the first infusion.

Conditions

COVID - 19

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

γδ T cells (IMP, TCB008)

Patients will receive an infusion of γδ T cells (IMP, TCB008) following informed consent after admission to hospital for SARS-CoV-2 infection (COVID-19).

Group Type: EXPERIMENTAL

TCB008

Intervention Type: DRUG

administration of gamma delta T cells by IV bolus injection

Interventions

TCB008

administration of gamma delta T cells by IV bolus injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF);

• willingness and capability to complete all the study procedures

2. Age 18-65 years (inclusive) at the time of signing ICF

3. Any gender

4. Patients with a positive diagnosis of COVID-19 either identified in the community as at risk of progression of disease or

• already hospitalized with new changes on CXR or CT scan compatible with COVID19, or
• patients requiring supplemental oxygen, but for whom dexamethasone is not yet indicated according to current standard of care recommendations.

The product would be indicated for patients categorized as per the WHO ordinal scale 2,3 or 4: i.e., ambulatory (or community identified) patients with limitations of activity, judged as at risk for progression of disease, as well as hospitalized patients not yet requiring oxygen therapy or receiving non-invasive low flow oxygen therapy, which does not yet indicate the need to commence dexamethasone therapy.

Exclusion Criteria

1. Patients requiring high-flow oxygen therapy and/or dexamethasone according to the current standard of care.

2. Patients suffering from severe cognitive impairment or mental illness

3. Pregnant and/or lactating women

4. Patients participating in other CTIMP clinical studies at the same time

5. Active autoimmune disease or Graft versus Host Disease (GVHD)

6. Patients with any major comorbidity (e.g., diabetes, cardiovascular and pulmonary diseases, malignancies on active treatment) unless their pre-morbid Karnofsky performance status was ≥ 80%

7. Patients with documented history of immunological disorders

8. Immunocompromised patients defined as those with human immunodeficiency virus infection with a CD4 cell count of less than 200 per microliter or uncontrolled viremia, prolonged use of glucocorticoids or other immunomodulating medications, a history of bone marrow or organ transplantation

9. ALT / AST> 5 times the upper limit of the normal

10. Neutrophils <500 / mm3

11. Platelets <50.000 / mm3

12. Patients known or suspected to have sensitivity against mouse immunoglobulins or iron-dextran.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

TC Biopharm

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Royal Victoria Infirmary

Newcastle, , United Kingdom

Countries

United Kingdom

Other Identifiers

TCB008-002

Identifier Type: -

Identifier Source: org_study_id